TeraRecon’s Eureka Clinical AI Platform Automates Cardiovascular Disease Diagnosis Utilizing Advanced AI
TeraRecon, an advanced visualization and clinical AI SaaS company, has unveiled its Cardio Suite on the Eureka Clinical AI platform. This new solution leverages artificial intelligence (AI) and deep learning technology to assist healthcare providers in identifying, treating, and managing cardiovascular disease.
Eureka Clinical AI, a globally deployed clinical AI hosting solution, serves as a host for TeraRecon’s first-party and third-party AI solutions. It integrates these solutions into standardized workflows across healthcare enterprises. With the integration of the Cardio Suite into the Eureka Clinical AI platform, clinicians gain access to powerful AI tools that streamline image processing and interpretation, enhance diagnostic accuracy, and facilitate care coordination for cardiac patients.
Dan McSweeney, President of TeraRecon, expressed the company’s commitment to supporting cardiologists and clinicians by introducing innovative AI-powered solutions. The Cardio Suite, powered by partners Us2.ai and Coreline Soft, aims to automate the analysis and interpretation of echocardiograms and chest CT exams. Us2.ai’s patented automated clinical workflow solution, Us2.v1, plays a pivotal role in reducing the time required to process and interpret echocardiograms. It achieves this without variability and accuracy comparable to expert clinicians. By automating measurements and generating comprehensive echo reports based on international guidelines, Us2.ai’s technology enhances workflow efficiency while maintaining high accuracy. The Coreline Soft AVIEW CAC AI algorithm streamlines the measurement of coronary artery calcification (CAC) scores, a strong predictor of coronary events. AVIEW CAC AI automates a process that would otherwise be time-consuming and is compatible with low-dose CTs without ECG-gating, reducing costs and radiation doses to patients.
The Eureka Clinical AI platform not only enables the deployment of these advanced AI solutions but also provides robust notification and communication tools. These tools support healthcare providers in making time-sensitive decisions and coordinating multidisciplinary care teams efficiently.
The Cardio Suite applications on the Eureka Clinical AI platform have received FDA approval, CE clearance, and additional regional clearances.
The expansion of TeraRecon’s AI offerings underscores the growing role of AI in healthcare, where it continues to enhance diagnostics, treatment decisions, and overall patient care. As AI-powered solutions become more integrated into clinical practice, the future holds the promise of more efficient, accurate, and accessible healthcare for patients worldwide.